PCN16 the Clinical Outcomes and Costs of Treating Oncology Patients for Severe Sepsis (original) (raw)
A real-world study assessing the use of bone-targeted agents and their impact on bone metastases in patients with prostate cancer treated in clinical practice in Europe
Roger Von Moos
Journal of Bone Oncology, 2018
View PDFchevron_right
Combined Analysis of Two Multicenter, Randomized, Placebo-Controlled Studies of Pamidronate Disodium for the Palliation of Bone Pain in Men With Metastatic Prostate Cancer
MIldred Kowalski
Journal of Clinical Oncology, 2003
View PDFchevron_right
Cost-Effectiveness Analysis of 12-Versus 4-Weekly Administration of Bone-Targeted Agents in Patients with Bone Metastases from Breast and Castration-Resistant Prostate Cancer
Terry En Gee
Current Oncology, 2021
View PDFchevron_right
Strategies for Management of Prostate Cancer-Related Bone Pain
R. Pelger
Drugs & Aging, 2001
View PDFchevron_right
Bicalutamide 150 mg: practical prescribing in patients with early prostate cancer
John Anderson
BJU International, 2004
View PDFchevron_right
Less pain does equal better quality of life following strontium-89 therapy for metastatic prostate cancer
Sandra Turner
British journal of cancer, 2001
View PDFchevron_right
Bone health management in the continuum of prostate cancer disease: a review of the evidence with an expert panel opinion
Toni Ibrahim
ESMO Open, 2020
View PDFchevron_right
Painful bone metastases in hormone???refractory prostate cancer: economic costs of Strontium???89 and/or external radiotherapy
Derek J Rosario
Curr Opin Urol, 1998
View PDFchevron_right
Costs of Prostate Cancer, Metastatic to the Bone, in The Netherlands
R. Pelger
European Urology, 2003
View PDFchevron_right
Cost-effective models for flutamide for prostate carcinoma patients: Are they helpful to policy makers?
D. Matchar
Cancer, 1996
View PDFchevron_right
Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer
Manfred Wirth
BJU International, 2006
View PDFchevron_right
Treatment considerations for persons with metastatic prostate cancer: Survival versus out-of-pocket costs
D. Matchar
Urology, 1997
View PDFchevron_right
Patterns of care and economic consequences of using bone-targeted agents for castration-sensitive prostate cancer patients with bone metastases to prevent skeletal-related events in Switzerland – the SAKK 95/16 prostate study
Roger Von Moos
Swiss Medical Weekly, 2021
View PDFchevron_right
Evidence-based consensus recommendations to improve the quality of life in prostate cancer treatment
Jose Lopez Torrecilla
Clinical & Translational Oncology, 2010
View PDFchevron_right
Healthcare utilization and costs associated with skeletal-related events in prostate cancer patients with bone metastases
May Hagiwara
Prostate Cancer and Prostatic Diseases, 2013
View PDFchevron_right
Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747)
stuart collins
BJU international, 2016
View PDFchevron_right
The AVOCAT study: Bicalutamide monotherapy versus combined bicalutamide plus dutasteride therapy for patients with locally advanced or metastatic carcinoma of the prostate—a long-term follow-up comparison and quality of life analysis
Siebren Dijkstra
SpringerPlus, 2016
View PDFchevron_right
Chemotherapeutic impact on pain and global health-related quality of life in hormone-refractory prostate cancer: Dynamically Modified Outcomes (DYNAMO) analysis of a randomized controlled trial
Yoshi Nakamura
Quality of Life Research, 2009
View PDFchevron_right
Clinical recommendations in the management of advanced prostate cancer: International Gastrointestinal, Liver and Uro-oncology (IGILUC 2019) experts
Hesham Tawfik
World Journal of Urology, 2020
View PDFchevron_right
Single-center, retrospective study on changes in pain-relieving therapy after bone metastasis detection by bone scintigraphy in prostate cancer patients
Marcella Cardoso
Brazilian Journal of Pharmaceutical Sciences
View PDFchevron_right
Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019
Noel Clarke
European Urology, 2020
View PDFchevron_right
New Research Findings on Clinical Benefits of Bisphosphonates in Patients With Advanced Prostate Cancer
Noel Clarke
European Urology Supplements, 2006
View PDFchevron_right
Management of patients with advanced prostate cancer: Recommendations of the St.Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015
G. Daugaard
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, 2015
View PDFchevron_right
Management of Advanced Prostate Cancer
Auro del Giglio
The Oncologist, 2000
View PDFchevron_right
Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017
Raja Khauli
European urology, 2017
View PDFchevron_right
Quality of analgesic treatment in patients with advanced prostate cancer: do we do a better job now? The Swiss Group for Clinical Cancer Research (SAKK) experience
Rudolf Morant
Supportive Care in Cancer, 2007
View PDFchevron_right
TRAPEZE: a randomised controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid, strontium-89, or both, in men with bony metastatic castration-refractory prostate cancer
Andrew Stanley
Health Technology Assessment, 2016
View PDFchevron_right
Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial
Ethan Basch
The Lancet Oncology, 2014
View PDFchevron_right
Endocrine therapy in prostate cancer: Time for reappraisal of risks, benefits and cost-effectiveness?
Derek J Rosario
2013
View PDFchevron_right